Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 2/2009

01-06-2009 | Original Article

Bone biomechanical and histomorphometrical investment in type 2 diabetic Goto-Kakizaki rats

Authors: Liping Zhang, Yaping Liu, Dong Wang, Xinbo Zhao, Zhanjun Qiu, Hong Ji, Haiqin Rong

Published in: Acta Diabetologica | Issue 2/2009

Login to get access

Abstract

This study was performed to characterize the bone metabolism in ten 6-month-old male Goto-Kakizaki (GK) rats, a spontaneous type 2 diabetic model, with ten age- and sex-matched non-diabetic Wistar rats as controls. The femora and the fifth lumbar vertebrae were analyzed by a dual energy X-ray absorptiometry for bone mineral density. Histomorphometrical analyses were performed on the sections from the tibia embedded in methylmethacrylate. Biomechanical characterizations were made by a three-point bending test and a compressive test on the femur and the fifth vertebral body respectively. Compared to the control rats, the bone mineral density was significantly deceased and the histomorphometrical studies showed significantly decreased trabecular bone volume, trabecular thickness and number, osteoid surface and thickness, mineralizing surface, mineral apposition rate and bone formation rate, and also a significant increase in mineralization lag time in the diabetic rats. Strength in both bones and elastic modulus of vertebral body significantly decreased in the diabetic rats as well. In addition, the serum osteocalcin levels were significantly decreased and the serum tartrate-resistant acid phosphatase activity was significantly increased. In conclusion, the 6-month-old GK diabetic rats developed osteopenia with an increased risk of fracture owing to the decreased bone formation, and might be a useful model for unraveling the effects of diabetes on bones independent of obesity frequently seen in the type 2 diabetic patients.
Literature
1.
Albright F, Reifenstein E (1948) Parathyroid glands and metabolic bone disease: selected studies. Williams and Wilkins, Baltimore
2.
Lopez-Ibarra PJ, Pastor MM, Escobar-Jimenez F, Pardo MD, Gonzalez AG, Luna JD, Requena ME, Diosdado MA (2001) Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. Endocr Pract 7:346–351PubMed
3.
Bauer DC, Browner WS, Cauley JA, Orwoll ES, Scott JC, Black DM, Tao JL, Cummings SR (1993) Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 118:657–665PubMed
4.
Tuominen JT, Impivaara O, Puukka P, Ronnemaa T (1999) Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 22:1196–1200PubMedCrossRef
5.
Hanley DA, Brown JP, Tenenhouse A, Olszynski WP, Ioannidis G, Berger C, Prior JC, Pickard L, Murray TM, Anastassiades T, Kirkland S, Joyce C, Joseph L, Papaioannou A, Jackson SA, Poliquin S, Adachi JD (2003) Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res 18:784–790PubMedCrossRef
6.
Albala C, Yanez M, Devoto E, Sostin C, Zeballos L, Santos JL (1996) Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord 20:1027–1032PubMed
7.
Ahmad T, Ohlsson C, Saaf M, Ostenson CG, Kreicbergs A (2003) Skeletal changes in type-2 diabetic Goto-Kakizaki rats. J Endocrinol 178:111–116PubMedCrossRef
8.
Östenson CG (2001) The Goto-Kakizaki rat. In: Sima A, Shafrir E (eds) Animal models in diabetes: a primer (Frontiers in Animal Diabetes Research). Harwood Academic Publishers, Amsterdam, pp 197–211
9.
Xu J, Rong HQ, Ji H, Wang D, Liu CY (2006) Effects of human parathyroid hormone related protein on osteoporosis of variectomized rats. Chin J Rheumatol 10:154–157
10.
Catala-Gregori P, Garcia V, Hernandez F, Madrid J, Ceron JJ (2006) Response of broilers to feeding low-calcium and phosphorus diets plus phytase under different environmental conditions: body weight and tibiotarsus mineralization. Poult Sci 85:1923–1931PubMed
11.
Mattila P, Knuuttila M, Kovanen V, Svanberg M (1999) Improved bone biomechanical properties in rats after oral xylitol administration. Calcif Tissue Int 64:340–344PubMedCrossRef
12.
13.
Erben RG (1997) Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J Histochem Cytochem 45:307–313PubMed
14.
Miyakoshi N, Sato K, Abe T, Tsuchida T, Tamura Y, Kudo T (1999) Histomorphometric evaluation of the effects of ovariectomy on bone turnover in rat caudal vertebrae. Calcif Tissue Int 64:318–324PubMedCrossRef
15.
Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRef
16.
Botolin S, McCabe LR (2006) Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 99:411–424PubMedCrossRef
17.
Gopalakrishnan V, Vignesh RC, Arunakaran J, Aruldhas MM, Srinivasan N (2006) Effects of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages. Biochem Cell Biol 84:93–101PubMedCrossRef
18.
Verhaeghe J, Suiker AM, Visser WJ, Van Herck E, Van Bree R, Bouillon R (1992) The effects of systemic insulin, insulin-like growth factor-I and growth hormone on bone growth and turnover in spontaneously diabetic BB rats. J Endocrinol 134:485–492PubMedCrossRef
19.
Ahmad T, Ugarph-Morawski A, Lewitt MS, Li J, Saaf M, Brismar K (2008) Diabetic osteopathy and the IGF system in the Goto-Kakizaki rat. Growth Horm IGF Res 18:404–411PubMedCrossRef
20.
Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int 18:427–444PubMedCrossRef
21.
Portha B (2005) Programmed disorders of beta-cell development and function as one cause for type 2 diabetes? The GK rat paradigm. Diabetes Metab Res Rev 21:495–504PubMedCrossRef
22.
Augat P, Reeb H, Claes LE (1996) Prediction of fracture load at different skeletal sites by geometric properties of the cortical shell. J Bone Miner Res 11:1356–1363PubMed
23.
Fuse H, Fukumoto S, Sone H, Miyata Y, Saito T, Nakayama K, Takahashi H, Matsumoto T, Ogata E (1997) A new synthetic steroid, osaterone acetate (TZP-4238), increases cortical bone mass and strength by enhancing bone formation in ovariectomized rats. J Bone Miner Res 12:590–597PubMedCrossRef
24.
Kanter M, Altan MF, Donmez S, Ocakci A, Kartal ME (2007) The effects of quercetin on bone minerals, biomechanical behavior, and structure in streptozotocin-induced diabetic rats. Cell Biochem Funct 25:747–752PubMedCrossRef
25.
Verhaeghe J, Suiker AM, Einhorn TA, Geusens P, Visser WJ, Van Herck E, Van Bree R, Magitsky S, Bouillon R (1994) Brittle bones in spontaneously diabetic female rats cannot be predicted by bone mineral measurements: studies in diabetic and ovariectomized rats. J Bone Miner Res 9:1657–1667PubMed
26.
Ortoft G, Oxlund H (1988) Reduced strength of rat cortical bone after glucocorticoid treatment. Calcif Tissue Int 43:376–382PubMedCrossRef
27.
(2000 March 27–29) Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 17:1–36
28.
Ostenson CG, Fiere V, Ahmed M, Lindstrom P, Brismar K, Brismar T, Kreicbergs A (1997) Decreased cortical bone thickness in spontaneously non-insulin-dependent diabetic GK rats. J Diabetes Complications 11:319–322PubMedCrossRef
29.
Rakic V, Davis WA, Chubb SA, Islam FM, Prince RL, Davis TM (2006) Bone mineral density and its determinants in diabetes: the fremantle diabetes study. Diabetologia 49:863–871PubMedCrossRef
30.
Perez-Castrillon JL, De Luis D, Martin-Escudero JC, Asensio T, del Amo R, Izaola O (2004) Non-insulin-dependent diabetes, bone mineral density, and cardiovascular risk factors. J Diabetes Complicat 18:317–321PubMedCrossRef
31.
32.
33.
Amir G, Rosenmann E, Sherman Y, Greenfeld Z, Ne’eman Z, Cohen AM (2002) Osteoporosis in the Cohen diabetic rat: correlation between histomorphometric changes in bone and microangiopathy. Lab Invest 82:1399–1405PubMed
34.
Liu R, Bal HS, Desta T, Krothapalli N, Alyassi M, Luan Q, Graves DT (2006) Diabetes enhances periodontal bone loss through enhanced resorption and diminished bone formation. J Dent Res 85:510–514PubMedCrossRef
35.
Burkemper KM, Garris DR (2006) Influences of obese (ob/ob) and diabetes (db/db) genotype mutations on lumber vertebral radiological and morphometric indices: skeletal deformation associated with dysregulated systemic glucometabolism. BMC Musculoskelet Disord 7:10PubMedCrossRef
36.
Oz SG, Guven GS, Kilicarslan A, Calik N, Beyazit Y, Sozen T (2006) Evaluation of bone metabolism and bone mass in patients with type-2 diabetes mellitus. J Natl Med Assoc 98:1598–1604PubMed
37.
Cutrim DM, Pereira FA, de Paula FJ, Foss MC (2007) Lack of relationship between glycemic control and bone mineral density in type 2 diabetes mellitus. Braz J Med Biol Res 40:221–227PubMed
38.
Williams JP, Blair HC, McDonald JM, McKenna MA, Jordan SE, Williford J, Hardy RW (1997) Regulation of osteoclastic bone resorption by glucose. Biochem Biophys Res Commun 235:646–651PubMedCrossRef
39.
Morohoshi M, Fujisawa K, Uchimura I, Numano F (1996) Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 45:954–959PubMedCrossRef
40.
Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, Taketomi S (1997) Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 8:260–270PubMed
Metadata
Title
Bone biomechanical and histomorphometrical investment in type 2 diabetic Goto-Kakizaki rats
Authors
Liping Zhang
Yaping Liu
Dong Wang
Xinbo Zhao
Zhanjun Qiu
Hong Ji
Haiqin Rong
Publication date
01-06-2009
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 2/2009
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-008-0068-1

Other articles of this Issue 2/2009

Acta Diabetologica 2/2009 Go to the issue

Original Article

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

Short Communication

Cardiometabolic risk and educational level in adult patients with type 1 diabetes

Original Article

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

Review Article

Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities

Original Article

Insulin resistance and exercise capacity in male children and adolescents with non-alcholic fatty liver disease

Letter to the Editor

Letter to the Editor re: the Letter to the Editor by Dr. David Samuel Henry Bell, MD regarding “The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis”
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits